- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04682353
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
A Randomized, Dose-range Finding Study to Evaluate Pharmacokinetics of Medroxyprogesterone Acetate Following a Single Subcutaneous Administration of TV-46046 in Healthy Women of Reproductive Age
The primary objective of this study is to evaluate and compare the pharmacokinetic profile of Medroxyprogesterone acetate following subcutaneous administration of 3 different doses of TV-46046 and a dose of Depo-subQ Provera in healthy female participants.
The secondary objectives of the study are to evaluate and compare the safety, local tolerability, and acceptability of a subcutaneous injection of 3 different doses of TV-46046 and a dose of Depo-subQ Provera in healthy female participants.
The total duration of the study for each participant is expected to be up to 19.5 months.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Santo Domingo, Dominican Republic, 99999
- Teva Investigational Site 18001
-
-
-
-
California
-
Cypress, California, United States, 90630
- Teva Investigational Site 14002
-
-
Texas
-
San Antonio, Texas, United States, 78209
- Teva Investigational Site 14003
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- has regular menstrual cycle (21 to 35 days)
- has a low risk of pregnancy (ie, sterilized, in exclusively same-sex partnership, abstinent, in monogamous relationship with vasectomized partner, using nonhormonal intrauterine device (IUD), or consistently using barrier methods of contraception)
- had a normal mammogram within the last year, if 40 years of age or older
NOTE- Additional criteria apply, please contact the investigator for more information.
Exclusion Criteria:
- has multiple risk factors for cardiovascular disease (eg, smoking, obesity, hypertension, known low HDL, high LDL, or high triglyceride levels)
- has current or history of ischemic heart disease
- has active thrombophlebitis, current or past history of thromboembolic disorders, cerebral vascular disease or stroke
- has systemic lupus erythematosus
- has rheumatoid arthritis on immunosuppressive therapy
- has unexplained vaginal bleeding
- has diabetes
- has strong family history of breast cancer (defined as one or more first degree relatives with breast cancer, breast cancer occurring before menopause in three or more family members, regardless of degree of relationship, and any male family member with breast cancer)
- has current or history of breast cancer, or undiagnosed mass detected by breast exam
- has current or history of cervical cancer
- has cirrhosis or liver tumors
- has known osteoporosis or osteopenia
- has history of diagnosed clinical depression or bipolar disorder, with or without suicidal ideation, and/or history of suicide attempt, except short-lived situational depression that did not require medication and has not recurred in last five years
- used MPA-containing injectable products in the past 12 months
- used a combined injectable contraceptive in the past 6 months
- used any of the following medications within 1 month prior to enrollment:
- any investigational drug
- oral contraceptives, contraceptive ring or patch
- levonorgestrel intrauterine system (LNG IUS) or contraceptive implant
- is participating in another clinical trial
- is pregnant
- desires to become pregnant in subsequent 24 months
- has been pregnant in last 3 months
- is currently lactating
NOTE- Additional criteria apply, please contact the investigator for more information.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 - 120 mg/0.4 mL
|
SC injection of 300 mg/mL (120 mg/0.4mL;
180 mg/0.6mL;
240 mg/0.8mL)
|
Experimental: Group 2 - 180 mg/0.6 mL
|
SC injection of 300 mg/mL (120 mg/0.4mL;
180 mg/0.6mL;
240 mg/0.8mL)
|
Experimental: Group 3 - 240 mg/0.8 mL
|
SC injection of 300 mg/mL (120 mg/0.4mL;
180 mg/0.6mL;
240 mg/0.8mL)
|
Active Comparator: Group 4 - 104 mg/0.65 mL
|
SC injection of 104 mg/0.65 mL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum MPA Concentration at Day 91 (C91)
Time Frame: Day 91
|
Day 91
|
Serum MPA Concentration at Day 182 (C182)
Time Frame: Day 182
|
Day 182
|
Serum MPA Concentration at Day 210 (C210)
Time Frame: Day 210
|
Day 210
|
Area Under the Serum Drug Concentration-Time Curve From Time 0 to Day 182 (AUC0-182) of MPA
Time Frame: Day 0 to Day 182
|
Day 0 to Day 182
|
Area Under the Serum Drug Concentration-Time Curve From Time 0 to Day 210 (AUC0-210) of MPA
Time Frame: Day 0 to Day 210
|
Day 0 to Day 210
|
Area Under the Serum Drug Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MPA
Time Frame: Day 0 to Day 365
|
Day 0 to Day 365
|
Maximum Observed Serum Concentration (Cmax) of Medroxyprogesterone Acetate (MPA)
Time Frame: Day 0 to Day 365
|
Day 0 to Day 365
|
Time to Reach Cmax (Tmax) of MPA
Time Frame: Day 0 to Day 365
|
Day 0 to Day 365
|
Apparent Terminal Half-life (t½) of MPA
Time Frame: Day 0 to Day 365
|
Day 0 to Day 365
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame: Day 0 up to Week 78
|
Day 0 up to Week 78
|
|
Change From Baseline in Body Weight at Day 7 and Weeks 13, 26, and 52
Time Frame: Day 7 and Weeks 13, 26, and 52
|
Day 7 and Weeks 13, 26, and 52
|
|
Estradiol Concentrations
Time Frame: Baseline, Weeks 4, 13, 26, 30, and 52
|
Baseline, Weeks 4, 13, 26, 30, and 52
|
|
Number of Participants With at Least 1 Concomitant Medication Use During Treatment
Time Frame: Day 0 up to Week 78
|
Concomitant medications included acetic acid derivatives and substances, aminoalkyl ethers, anilides, calcium compounds, other viral vaccines, and propionic acid derivatives etc.
|
Day 0 up to Week 78
|
Number of Participants With Clinically Significant Changes in Vital Signs
Time Frame: Day 0 to Day 365
|
Vital signs examination included blood pressure, respiration rate, pulse, and body temperature.
|
Day 0 to Day 365
|
Number of Participants With Overall Opinion of Vaginal Bleeding Pattern
Time Frame: Weeks 13, 26, and 52
|
Number of participants with overall opinion of vaginal bleeding pattern as acceptable or not acceptable has been reported.
|
Weeks 13, 26, and 52
|
Number of Participants With Patient Health Questionnaire (PHQ-9) Mood Scores
Time Frame: Baseline, Weeks 4, 13, 26, and 52
|
The PHQ-9 is a participant-rated depressive symptom severity scale to monitor severity over time for newly diagnosed participants or participants in current treatment for depression.
Scoring was based on participants' responses to each of the 9 questions, as follows: 0=not at all; 1=several days; 2=more than half the days; and 3=nearly every day.
The PHQ-9 total score was calculated as the sum of the 9 individual item scores.
The PHQ-9 total score was categorized as follows: 0 = no depression, 1 to 4=minimal depression, 5 to 9=mild depression, 10 to 14=moderate depression, 15 to 19=moderately severe depression; and 20 to 27=severe depression.
Higher scores indicate more severe depression.
|
Baseline, Weeks 4, 13, 26, and 52
|
Number of Participants With Clinically Significant Changes in Liver Function Tests
Time Frame: Day 0 to Day 365
|
Day 0 to Day 365
|
|
Number of Participants With No Ovulation in 12 Months
Time Frame: 12 months
|
Ovulation was defined as one or more progesterone measurements ≥ 4.7 ng/mL in Weeks 48, 49, 50, 51 or 52.
|
12 months
|
Number of Participants With 1 or More Injection Site Reactions (ISRs)
Time Frame: Day 0 to Day 365
|
The ISRs included erythema, swelling, pruritus, bleeding, tenderness, bruising, hypopigmentation, atrophy, and injection site pain.
|
Day 0 to Day 365
|
Number of Participants With Responses to the Acceptability Question (What do You Like About the Method?)
Time Frame: Weeks 26 and 52
|
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
|
Weeks 26 and 52
|
Number of Participants With Responses to the Acceptability Question (What do You Not Like About the Method?)
Time Frame: Weeks 26 and 52
|
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
|
Weeks 26 and 52
|
Number of Participants With Responses to the Acceptability Question (If You Were at Risk for Pregnancy, Would You Use This Method of Contraception Outside of This Study?)
Time Frame: Weeks 26 and 52
|
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
|
Weeks 26 and 52
|
Number of Participants With Responses to the Acceptability Question (If You Had a Choice, Which Injectable Contraceptive Method Would You Prefer?)
Time Frame: Weeks 26 and 52
|
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
|
Weeks 26 and 52
|
Progesterone Concentration
Time Frame: Weeks 48, 49, 50, 51, and 52
|
Weeks 48, 49, 50, 51, and 52
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Teva Medical Expert, MD, Teva Branded Pharmaceutical Products R&D, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Contraceptive Agents, Male
- Medroxyprogesterone Acetate
- Medroxyprogesterone
Other Study ID Numbers
- TV46046-WH-10159
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Montefiore Medical CenterSociety of Family PlanningCompletedContraception | Breastfeeding | Postpartum ContraceptionUnited States
Clinical Trials on TV-46046
-
Teva Branded Pharmaceutical Products R&D, Inc.FHI 360Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.FHI 360CompletedContraceptionDominican Republic
-
University of VermontUnited States Department of Agriculture (USDA)CompletedObesity | OverweightUnited States
-
Seattle Children's HospitalWithdrawn
-
Children's Hospital of Eastern OntarioCompleted
-
Lady Davis InstituteNot yet recruitingQuality of Life | Stress | Patient Engagement | Loneliness
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health... and other collaboratorsActive, not recruitingTricuspid Regurgitation | Mild Tricuspid Regurgitation | Moderate Tricuspid RegurgitationUnited States, Canada, Germany
-
Herlev HospitalUniversity of Copenhagen; Bispebjerg Hospital; University Hospital, Gentofte,...TerminatedPain | Surgery | CholecystolithiasisDenmark
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom, Latvia
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedPharmacokineticsUnited States